Abstract
Women have a higher percentage of body fat than men, and there is a gender-specific difference in fat distribution: Females tend to accumulate fat around the hips, buttocks, and thighs while men have a larger intra-abdominal (visceral) fat mass. After menopause, there is a redistribution of fat depots, and post-menopausal women develop increased amounts of visceral fat. The risk of developing obesity-related diseases is significantly lower in pre-menopausal women compared to men, a difference that is abolished after menopause, suggesting that the female sex steroid estrogen influences adipogenesis and adipose metabolism. Experimentally, estrogen increases the size and number of subcutaneous adipocytes and attenuates lipolysis. Post-menopausal women also develop a more atherogenic lipid pattern and decreased levels of the prothrombotic protein plasminogen activator inhibitor-1, which attenuates fibrinolysis. Pathologically increased circulating cortisol concentration is associated with dysmetabolic features e.g., central obesity, elevated blood pressure, insulin resistance, and dyslipidemia. In “simple obesity,” glucocorticoid production is elevated. Peak levels of circulating cortisol are however low or normal, possibly because of increased clearance and/or tissue-specific changes in cortisol production. In addition to the adrenal production of cortisol, cortisol is also generated in adipose tissue by the enzyme 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) which converts inactive cortisone to active cortisol. The enzyme activity in subcutaneous fat increases with increasing body weight. Estrogen seems to have a tissue-specific influence on 11βHSD1 enzyme activity, attenuating it in liver, kidney, and testis but upregulating 11βHSD1 mRNA expression in preadipocytes from women. In the present review, we summarize and discuss the interaction between glucocorticoids and sex steroids and their influence on adipocyte metabolism.
Keywords: Adipose tissue, metabolic syndrome, estrogen, 11β-hydroxysteroid dehydrogenase, cortisol
Current Medicinal Chemistry
Title: Estrogens and Glucocorticoid Hormones in Adipose Tissue Metabolism
Volume: 14 Issue: 27
Author(s): Cecilia Mattsson and Tommy Olsson
Affiliation:
Keywords: Adipose tissue, metabolic syndrome, estrogen, 11β-hydroxysteroid dehydrogenase, cortisol
Abstract: Women have a higher percentage of body fat than men, and there is a gender-specific difference in fat distribution: Females tend to accumulate fat around the hips, buttocks, and thighs while men have a larger intra-abdominal (visceral) fat mass. After menopause, there is a redistribution of fat depots, and post-menopausal women develop increased amounts of visceral fat. The risk of developing obesity-related diseases is significantly lower in pre-menopausal women compared to men, a difference that is abolished after menopause, suggesting that the female sex steroid estrogen influences adipogenesis and adipose metabolism. Experimentally, estrogen increases the size and number of subcutaneous adipocytes and attenuates lipolysis. Post-menopausal women also develop a more atherogenic lipid pattern and decreased levels of the prothrombotic protein plasminogen activator inhibitor-1, which attenuates fibrinolysis. Pathologically increased circulating cortisol concentration is associated with dysmetabolic features e.g., central obesity, elevated blood pressure, insulin resistance, and dyslipidemia. In “simple obesity,” glucocorticoid production is elevated. Peak levels of circulating cortisol are however low or normal, possibly because of increased clearance and/or tissue-specific changes in cortisol production. In addition to the adrenal production of cortisol, cortisol is also generated in adipose tissue by the enzyme 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) which converts inactive cortisone to active cortisol. The enzyme activity in subcutaneous fat increases with increasing body weight. Estrogen seems to have a tissue-specific influence on 11βHSD1 enzyme activity, attenuating it in liver, kidney, and testis but upregulating 11βHSD1 mRNA expression in preadipocytes from women. In the present review, we summarize and discuss the interaction between glucocorticoids and sex steroids and their influence on adipocyte metabolism.
Export Options
About this article
Cite this article as:
Mattsson Cecilia and Olsson Tommy, Estrogens and Glucocorticoid Hormones in Adipose Tissue Metabolism, Current Medicinal Chemistry 2007; 14 (27) . https://dx.doi.org/10.2174/092986707782359972
DOI https://dx.doi.org/10.2174/092986707782359972 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Novel Insights in Molecular Mechanisms of CLL
Current Pharmaceutical Design Functional Interactions Between B Lymphocytes and the Innate Immune System
Infectious Disorders - Drug Targets Targeting Epigenetics in Nervous System Disease
CNS & Neurological Disorders - Drug Targets Advantages and Limitations of Transgenic Mice: The Role of the Na<sup>+</sup>/Ca<sup>2+</sup> Exchanger in Cardiac Electrophysiology and Arrhythmia
Current Medicinal Chemistry Mesenchymal Stromal Cells from Umbilical Cord Blood
Current Stem Cell Research & Therapy Lactoferrin as a Natural Immune Modulator
Current Pharmaceutical Design Signal Transduction via Cannabinoid Receptors
CNS & Neurological Disorders - Drug Targets Herb-Drug Interactions and Mechanistic and Clinical Considerations
Current Drug Metabolism Do Advanced Glycation End Products (AGEs) Contribute to the Comorbidities of Polycystic Ovary Syndrome (PCOS)?
Current Pharmaceutical Design ADAM10 as a Therapeutic Target for Cancer and Inflammation
Current Pharmaceutical Design TRPC Channels and their Implications for Neurological Diseases
CNS & Neurological Disorders - Drug Targets Subject Index To Volume 7
Current Protein & Peptide Science The Interplay between the Gut Immune System and Microbiota in Health and Disease: Nutraceutical Intervention for Restoring Intestinal Homeostasis
Current Pharmaceutical Design The Regulation of FoxP3-Expressing Regulatory T Cells
Endocrine, Metabolic & Immune Disorders - Drug Targets Progress Towards Recombinant Anti-Infective Antibodies
Recent Patents on Anti-Infective Drug Discovery Role of CYP2E1 in Mitochondrial Dysfunction and Hepatic Injury by Alcohol and Non-Alcoholic Substances
Current Molecular Pharmacology Genetic and Epigenetic Heterogeneity in Cancer: The Ultimate Challenge for Drug Therapy
Current Drug Targets Potential Therapeutic Interest of Adenosine A2A Receptors in Psychiatric Disorders
Current Pharmaceutical Design Cross Currents in Protein Misfolding Disorders: Interactions and Therapy
CNS & Neurological Disorders - Drug Targets The Role of Coronary Physiology in Contemporary Percutaneous Coronary Interventions
Current Cardiology Reviews